Landos Biopharma, Inc. LABP NASDAQ

Landos Biopharma, Inc. (LABP) reported total assets of $29.9M and total liabilities of $6.74M for quarter ending 2024-03-31, resulting in total equity of $23.15M.

The company held $29.05M in cash and short-term investments. Total debt stood at $0.00, with net debt of $-29.05M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 4.43, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0, current ratio of 4.43 — balance sheet is strong
• MOAT (46/100) — Total assets $29.9M and equity $23.15M support the company's competitive scale

Overall SharesGrow Score: 39/100 with 1/7 criteria passed.